A Phase 1 Randomized, Double-Blinded, Active-Controlled, 2-Dose Study to Assess the Safety and Immunogenicity of a Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects 50 to 69 Years of Age
Latest Information Update: 24 Sep 2024
At a glance
- Drugs JCXH-105 (Primary) ; GSK 137173A
- Indications Herpes zoster
- Focus Adverse reactions; First in man
- Sponsors Immorna
Most Recent Events
- 13 Sep 2024 Status changed from active, no longer recruiting to completed.
- 24 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 30 May 2023 According to Immorna Therapeutics media release, the company announced that the first subject has been dosed in this study of JCXH-105, a self-replicating RNA (srRNA) vaccine being developed for the prevention of Shingles (Herpes Zoster; HZ).